Navigation Links
Abatacept as effective as adalimumab in rheumatoid arthritis
Date:6/12/2013

Madrid, Spain, 12 June 2013: Data from AMPLE presented at EULAR 2013, the Annual Congress of the European League Against Rheumatism, demonstrate comparable efficacy and similar safety profiles between subcutaneous abatacept (ABA) and adalimumab (ADA).

AMPLE, the first two-year head-to-head biologics trial, was comprised of 646 biologic-nave patients with active rheumatoid arthritis (RA) equally randomised to either ABA or ADA, with a stable dose of methotrexate (MTX). 79.2% (252 of 318) ABA patients and 74.7% (245 of 328) ADA patients completed the trial.

RA is a chronic autoimmune disease that principally attacks flexible joints. Affecting approximately 1 in 100 people worldwide, RA can cause pain, stiffness, progressive joint destruction and deformity, and reduce physical function, quality of life and life expectancy. At least 50% of RA patients in developed countries are unable to hold down a full-time job within 10 years of onset.2

"To date, there have been no randomised, controlled studies directly comparing the efficacy and safety of different biological DMARDs using the combination of a biologic medication and methotrexate, the most commonly prescribed treatment approach in moderate to severe RA", said lead author of the study Dr. Michael Schiff, University of Colorado, USA.

"This robust data set demonstrates that subcutaneous abatacept and adalimumab are equally efficacious in clinical, functional and radiographic outcomes. This study is a great leap forward for patients as it shows another treatment is as effective as adalimumab" Dr. Schiff concluded.

AMPLE is a Phase IIIb randomised, investigator-blinded study with a primary efficacy endpoint at day 365. Biologic-nave patients with active RA and an inadequate response to MTX were randomized to 125 mg ABA weekly (without an IV load) or 40 mg ADA bi-weekly, with a stable dose of MTX. All clinical efficacy endpoints were captured and read through day 729, including radiographs assessed using the van der Heijde modified Total Sharp score (mTSS), by readers blinded to treatment allocation and sequence.

At Year one, 64.8% ABA and 63.4% ADA patients were ACR20* responders. Consistent with Year one, clinical efficacy measures and inhibition of radiographical progression were comparable between groups at Year two. There were similar rates of adverse events (AE) and serious adverse events (SAE) in the ABA and ADA groups (13.8% vs. 16.5%) and malignancies (2.2% vs. 2.1%). More autoimmune AEs occurred in the ABA arm (3.8% vs. 1.8%); none were SAEs. Injection site reactions occurred less frequently in the ABA arm (4.1% vs. 10.4%). There were fewer discontinuations due to adverse events (3.8% vs. 9.5%), serious adverse events (1.6% vs. 4.9%), and due to serious infections (0/12 vs. 9/19 patients) in the ABA vs. ADA groups, respectively.

Abatacept (Orencia), produced by Bristol-Myers Squibb, is a first-in-class biologic which reduces co-stimulation of T-cells, in turn reducing activation of other cells in the inflammatory process, blocking the pain, inflammation and joint progression pathways in RA.

Adalimumab (Humira), produced by Abbott, is a biologic TNF-blocker (anti-TNF). Adalimumab binds to TNF-alpha receptors, blocking the pain, inflammation and joint progression pathways in RA.


'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-020-733-15364
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Head-to-head study in RA shows that abatacept has comparable efficacy to adalimumab
2. Daimer Offers Steam Cleaner Vacuums for Effective Restroom Cleaning in Commercial Settings
3. The Fight Against West Nile Virus Begins Again: Learn Simple, Effective Tips to Protect Yourself and Family
4. PET/MR effective for imaging recurrent prostate cancer
5. Rihanna Herpes and Lipstick Fiasco Shows Need for Effective Herpes Remedy; polyDNA Recommends Gene-Eden-VIR to Kill Latent Herpes Virus
6. Screening at-risk adolescents for celiac disease proves cost-effective
7. 2013 Report Confirms Effective Cyber Emergency Response Plan is Vital to Slash Data Breach Costs
8. hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offer New, Advanced Weight Loss Tips to Rapidly Reduce Weight and Increase Effective Stress Management
9. Everyday Vitamin Nutrition LLC Offers Most Potent and Effective Garcinia Cambogia for Appetite Suppression
10. African Mango Plus is Clinically Proven Effective Formula to Increase the Energy Level of the Body
11. ZetaClear the 2-Step Natural Formula is Now Available to Effectively Fight Against the Nail Fungus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... For over twenty-four years, Doctors on ... to help personal injury victims find high quality medical care. When the company started ... area. Fast forward to present day and the now ten-page directory features a vast ...
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... More than ... and while 84 percent of parents report speaking with their child about sex related ... sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its second ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre Springs beneath the ... its unmatched natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition ... has been available in several ShopRite and FoodTown stores in NJ and received rave ...
(Date:12/2/2016)... ... 02, 2016 , ... On November 24th, 2016, Thanksgiving morning, ... different sites throughout Miami-Dade and Broward counties. This is the largest meal delivery ... Thanksgiving morning by putting together individual meals via assembly lines and passing them ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec 1, 2016 Research ... "Drug Delivery in Cancer - Technologies, Markets and Companies" ... , ... challenge in management of cancer The market value of ... Cancer market estimates from 2015-2025 are given according to organs involved ...
(Date:12/2/2016)... 2016 Around the corners of world, cancer ... habitable land present over earth. Cancer has become one ... a life time this is because of the increasing ... Given the steady increase in global cancer incidence with ... healthcare costs of treatment, there is increasing interest in ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology: